Robert W. Baird Cuts Karyopharm Therapeutics (NASDAQ:KPTI) Price Target to $42.00

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) had its target price dropped by research analysts at Robert W. Baird from $54.00 to $42.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has an "outperform" rating on the stock.

Several other equities analysts have also recently commented on KPTI. Royal Bank of Canada reiterated an "outperform" rating and set a $45.00 target price on shares of Karyopharm Therapeutics in a research note on Thursday, February 20th. HC Wainwright increased their price objective on shares of Karyopharm Therapeutics from $7.00 to $56.00 and gave the stock a "buy" rating in a report on Wednesday, February 26th. One analyst has rated the stock with a sell rating and five have given a buy rating to the company's stock. According to MarketBeat, Karyopharm Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $43.20.

Karyopharm Therapeutics Trading Down 2.2%

NASDAQ:KPTI traded down $0.12 during trading hours on Tuesday, hitting $5.32. 35,974 shares of the company traded hands, compared to its average volume of 82,330. The stock has a market capitalization of $45.59 million, a price-to-earnings ratio of -5.22 and a beta of 0.33. Karyopharm Therapeutics has a twelve month low of $3.51 and a twelve month high of $17.85. The firm has a 50-day moving average of $5.37 and a 200 day moving average of $8.74.

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($2.77) EPS for the quarter, beating the consensus estimate of ($4.21) by $1.44. The company had revenue of $30.02 million for the quarter, compared to analyst estimates of $35.12 million. Equities research analysts predict that Karyopharm Therapeutics will post -0.71 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Karyopharm Therapeutics

A number of hedge funds have recently added to or reduced their stakes in KPTI. T. Rowe Price Investment Management Inc. acquired a new stake in shares of Karyopharm Therapeutics in the 1st quarter valued at approximately $523,000. Velan Capital Investment Management LP acquired a new stake in shares of Karyopharm Therapeutics in the 4th quarter valued at approximately $27,000. Two Sigma Advisers LP raised its position in shares of Karyopharm Therapeutics by 145.5% in the 4th quarter. Two Sigma Advisers LP now owns 76,600 shares of the company's stock valued at $52,000 after acquiring an additional 45,400 shares during the period. Two Sigma Investments LP raised its holdings in Karyopharm Therapeutics by 60.3% during the 4th quarter. Two Sigma Investments LP now owns 137,786 shares of the company's stock worth $93,000 after buying an additional 51,856 shares during the period. Finally, Shay Capital LLC acquired a new stake in Karyopharm Therapeutics during the 4th quarter worth approximately $116,000. Institutional investors own 66.44% of the company's stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).